FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial ...

Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Rais ...

There is a promising shift toward non-surgical treatment strategies in early breast cancer, as clinicians aim to reduce harm ...

Gastric cancer remains a major health challenge worldwide, with nearly 1 million new cases annually contributing to more than ...

Robot-assisted breast cancer surgery is changing everything—discover why top doctors are choosing it for unmatched precision, ...

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Discover AstraZeneca's Q1 2025 performance with 10% revenue growth, innovative medicines, and bold 2030 goals.

Following results from their new retrospective study, the researchers suggested that immediate reconstruction of the nose ...

Core operating income margin was 42.1% of net sales ... including +87% growth in the US with strong momentum from the recently launched early breast cancer indication as well as continued share gains ...

The elderly lawmaker beat Congresswoman Alexandria Ocasio-Cortez in a race for the post atop the Oversight Committee in ...